|Trade names||Pentothal, Sodium Pentothal, Trapanal, others|
|Other names||Thiopental sodium, thiopental, thiopentone, truth serum|
|Main uses||Induction of anesthesia, status epilepticus, raised intracranial pressure|
|Side effects||Arrhythmias, decreased strength of heart contractions|
|Intravenous (most common), by mouth, rectal|
|Onset of action||< 45 sec|
|Duration of action||5–15 min|
|Elimination half-life||5.5–26 hours|
|Chemical and physical data|
|Molar mass||264.32 g·mol−1|
|3D model (JSmol)|
Sodium thiopental, also known as thiopental and sold under the brand names Trapanal among others, is a general anesthetic. It is used for induction of anesthesia, status epilepticus, and raised intracranial pressure in people who are ventilated. It is given by injection into a vein. Onset is less than 45 seconds with a duration of action of about 5 to 15 minutes.
Common side effects include stopping of breathing, arrhythmias and decreased strength of heart contractions. Anaphylaxis may occur, as may tissue death if injected into soft tissue. There is a moderate risk of misuse. Breastfeeding may occur after use. It is a barbiturate and works by slowing brain activity.
Sodium thiopental was discovered in 1934. It is on the World Health Organization's List of Essential Medicines as an alternative to propofol. It is no longer sold in the United States since 2011. In the United Kingdom a 500 mg vial costs the NHS about £6 as of 2023.
Sodium thiopental is an ultra-short-acting barbiturate and has been used commonly in the induction phase of general anesthesia. Its use has been largely replaced with that of propofol, but may retain some popularity as an induction agent for rapid-sequence induction and intubation, such as in obstetrics. Following intravenous injection, the drug rapidly reaches the brain and causes unconsciousness within 30–45 seconds. At one minute, the drug attains a peak concentration of about 60% of the total dose in the brain. Thereafter, the drug distributes to the rest of the body, and in about 5–10 minutes the concentration is low enough in the brain that consciousness returns.
A normal dose of sodium thiopental (usually 4–6 mg/kg) given to a pregnant woman for operative delivery (caesarean section) rapidly makes her unconscious, but the baby in her uterus remains conscious. However, larger or repeated doses can depress the baby's consciousness.
Sodium thiopental is not used to maintain anesthesia in surgical procedures because, in infusion, it displays zero-order elimination pharmacokinetics, leading to a long period before consciousness is regained. Instead, anesthesia is usually maintained with an inhaled anesthetic (gas) agent. Inhaled anesthetics are eliminated relatively quickly, so that stopping the inhaled anesthetic will allow rapid return of consciousness. Sodium thiopental would have to be given in large amounts to maintain unconsciousness during anaesthesia due to its rapid redistribution throughout the body (as it has a high volume of distribution). Since its half-life of 5.5 to 26 hours is quite long, consciousness would take a long time to return.
In veterinary medicine, sodium thiopental is used to induce anesthesia in animals. Since it is redistributed to fat, certain lean breeds of dogs such as sighthounds will have prolonged recoveries from sodium thiopental due to their lack of body fat and their lean body mass. Conversely, obese animals will have rapid recoveries, but it will take much longer for the drug to be entirely removed (metabolized) from their bodies. Sodium thiopental is always administered intravenously, as it can be fairly irritating to tissue and is a vesicant; severe tissue necrosis and sloughing can occur if it is injected incorrectly into the tissue around a vein.
Sodium thiopental was historically used to induce medical comas. It has now been superseded by drugs such as propofol because their effects wear off more quickly. People with brain swelling, causing elevation of intracranial pressure, either secondary to trauma or following surgery, may benefit from this drug. Sodium thiopental, and the barbiturate class of drugs, decrease neuronal activity thereby decreasing cerebral metabolic rate of oxygen consumption (CMRO2), decrease the cerebrovascular response to carbon dioxide, which in turn decreases intracranial pressure. Patients with refractory elevated intracranial pressure (RICH) due to traumatic brain injury (TBI) may have improved long term outcome when barbiturate coma is added to their neurointensive care treatment. Reportedly, thiopental has been shown to be superior to pentobarbital in reducing intracranial pressure. This phenomenon is also called an inverse steal or Robin Hood effect as cerebral perfusion to all parts of the brain is reduced (due to the decreased cerebrovascular response to carbon dioxide) allowing optimal perfusion to ischaemic areas of the brain which have higher metabolic demands, since vessels supplying ischaemic areas of the brain would already be maximally dilated because of the metabolic demand.
In refractory status epilepticus, thiopental may be used to terminate a seizure.
Sodium thiopental is used intravenously for the purposes of euthanasia. In both Belgium and the Netherlands, where active euthanasia is allowed by law, the standard protocol recommends sodium thiopental as the ideal agent to induce coma, followed by pancuronium bromide to paralyze muscles and stop breathing.
Intravenous administration is the most reliable and rapid way to accomplish euthanasia. Death is quick. A coma is first induced by intravenous administration of 20 mg/kg thiopental sodium (Nesdonal) in a small volume (10 ml physiological saline). Then, a triple dose of a non-depolarizing neuromuscular blocking drug is given, such as 20 mg pancuronium bromide (Pavulon) or 20 mg vecuronium bromide (Norcuron). The muscle relaxant should be given intravenously to ensure optimal bioavailability but pancuronium bromide may be administered intramuscularly at an increased dosage level of 40 mg.
Psychiatrists have used thiopental to desensitize people with phobias and to "facilitate the recall of painful repressed memories." One psychiatrist who worked with thiopental is Jan Bastiaans, who used this procedure to help relieve trauma in survivors of the Holocaust.
The usual dose range for induction of anesthesia using thiopental is from 3 to 6 mg/kg; however, there are many factors that can alter this. Premedication with sedatives such as benzodiazepines or clonidine will reduce requirements due to drug synergy, as do specific disease states and other patient factors. Among patient factors are: age, sex, and lean body mass. Specific disease conditions that can alter the dose requirements of thiopentone and for that matter any other intravenous anaesthetic are: hypovolemia, burns, azotemia, liver failure, hypoproteinemia, etc.
As with nearly all anesthetic drugs, thiopental causes cardiovascular and respiratory depression resulting in hypotension, apnea, and airway obstruction. For these reasons, thiopental should only be administered by suitably trained medical personnel, who should give thiopental in an environment equipped to provide (respiratory) support, such as mechanical ventilation . Other side-effects include headache, agitated emergence, prolonged somnolence, and nausea. Intravenous administration of sodium thiopental is followed instantly by an odor and/or taste sensation, sometimes described as being similar to rotting onions, or to garlic. Residual side-effects may last up to 36 hours.
Thiopental should be used with caution in cases of liver disease, Addison's disease, myxedema, severe heart disease, severe hypotension, a severe breathing disorder, or a family history of porphyria.
Co-administration of pentoxifylline and thiopental causes death by acute pulmonary edema in rats. This pulmonary edema was not mediated by cardiac failure or by pulmonary hypertension but was due to increased pulmonary vascular permeability.
Mechanism of action
Sodium thiopental is a member of the barbiturate class of drugs, which are relatively non-selective compounds that bind to an entire superfamily of ligand-gated ion channels, of which the GABAA receptor channel is one of several representatives. This superfamily of ion channels includes the neuronal nicotinic acetylcholine receptor (nAChR), the 5-HT3 receptor, the glycine receptor and others. Surprisingly, while GABAA receptor currents are increased by barbiturates (and other general anesthetics), ligand-gated ion channels that are predominantly permeable for cationic ions are blocked by these compounds. For example, neuronal nAChR are blocked by clinically relevant anesthetic concentrations of both sodium thiopental and pentobarbital. Such findings implicate (non-GABAergic) ligand-gated ion channels, e.g. the neuronal nAChR, in mediating some of the (side) effects of barbiturates. The GABAA receptor is an inhibitory channel that decreases neuronal activity, and barbiturates enhance the inhibitory action of the GABAA receptor.
Thiopental rapidly and easily crosses the blood–brain barrier as it is a lipophilic molecule. As with all lipid-soluble anaesthetic drugs, the short duration of action of sodium thiopental is due almost entirely to its redistribution away from central circulation into muscle and fatty tissue, due to its very high lipid–water partition coefficient (approximately 10), leading to sequestration in fatty tissue. Once redistributed, the free fraction in the blood is metabolized in the liver by zero-order kinetics. Sodium thiopental is mainly metabolized to pentobarbital, 5-ethyl-5-(1'-methyl-3'-hydroxybutyl)-2-thiobarbituric acid, and 5-ethyl-5-(1'-methyl-3'-carboxypropyl)-2-thiobarbituric acid.
Sodium thiopental was discovered in the early 1930s by Ernest H. Volwiler and Donalee L. Tabern, working for Abbott Laboratories. It was first used in human beings on March 8, 1934, by Dr. Ralph M. Waters in an investigation of its properties, which were short-term anesthesia and surprisingly little analgesia. Three months later, Dr. John S. Lundy started a clinical trial of thiopental at the Mayo Clinic at the request of Abbott. Abbott continued to make the drug until 2004, when it spun off its hospital-products division as Hospira.
Thiopental is famously associated with a number of anesthetic deaths in victims of the attack on Pearl Harbor. These deaths, relatively soon after the drug's introduction, were said to be due to excessive doses given to shocked trauma patients. However, recent evidence available through freedom of information legislation was reviewed in the British Journal of Anaesthesia, which has suggested that this story was grossly exaggerated. Of the 344 wounded that were admitted to the Tripler Army Hospital, only 13 did not survive, and it is unlikely that thiopentone overdose was responsible for more than a few of these.
Society and culture
Along with pancuronium bromide and potassium chloride, thiopental is used in 34 states of the US to execute prisoners by lethal injection. A very large dose is given to ensure rapid loss of consciousness. Although death usually occurs within ten minutes of the beginning of the injection process, some have been known to take longer. The use of sodium thiopental in execution protocols was challenged in court after a study in the medical journal The Lancet reported autopsies of executed inmates showed the level of thiopental in their bloodstream was insufficient to cause unconsciousness although this is dependent on different factors and not just on the drug itself.
On December 8, 2009, Ohio became the first state to use a single dose of sodium thiopental for its capital execution, following the failed use of the standard three-drug cocktail during a recent execution, due to inability to locate suitable veins. Kenneth Biros was executed using the single-drug method.
Washington State became the second state in the US to use the single-dose sodium thiopental injections for executions. On September 10, 2010, the execution of Cal Coburn Brown was the first in the state to use a single-dose, single-drug injection. His death was pronounced approximately one and a half minutes after the intravenous administration of five grams of the drug. It was previously the first of three drugs administered during most lethal injections in the United States, but the US manufacturer Hospira stopped manufacturing the drug in 2011 and the European Union banned the export of the drug for this purpose.
After its use for the execution of Jeffrey Landrigan in the US, the United Kingdom introduced a ban on the export of sodium thiopental in December 2010, after it was established that no European supplies to the US were being used for any other purpose. The restrictions were based on "the European Union Torture Regulation (including licensing of drugs used in execution by lethal injection)". From 21 December 2011, the EU extended trade restrictions to prevent the export of certain medicinal products for capital punishment, stating that "the Union disapproves of capital punishment in all circumstances and works towards its universal abolition".
Thiopental is still used in places such as India as a truth serum to weaken the resolve of a subject and make the individual more compliant to pressure. Barbiturates decrease both higher cortical brain function and inhibition. It is hypothesized that because lying is a more mentally involving process than telling the truth, suppression of the higher cortical functions may lead to the uncovering of the truth. The drug tends to make subjects verbose and cooperative with interrogators; however, the reliability of confessions made under thiopental is questionable.
Following a shortage that led a court to delay an execution in California, a company spokesman for Hospira, the sole American manufacturer of the drug, objected to the use of thiopental in lethal injection. "Hospira manufactures this product because it improves or saves lives, and the company markets it solely for use as indicated on the product labeling. The drug is not indicated for capital punishment and Hospira does not support its use in this procedure." On January 21, 2011, the company announced that it would stop production of sodium thiopental from its plant in Italy, because it could not provide Italian authorities with guarantees that exported doses would not be used in executions. According to a company spokesperson, Italy was the only viable place where it could produce the drug, leaving the US without a supplier.
In October 2015 the U.S. Food and Drug Administration confiscated an overseas shipment of thiopental destined for the states of Arizona and Texas. FDA spokesman Jeff Ventura said in a statement, "Courts have concluded that sodium thiopental for the injection in humans is an unapproved drug and may not be imported into the country".
- "Thiopental". Drugs.com. Archived from the original on 10 September 2023. Retrieved 12 September 2023.
- "Thiopental sodium". BNF. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
- Seth (2009). Textbook Of Pharmacology. Elsevier India. p. SA111-PA14. ISBN 9788131211588. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
- Kost, Michael (2004). Moderate Sedation/Analgesia: Core Competencies for Practice. Elsevier Health Sciences. p. 114. ISBN 9780721603247. Archived from the original on 2023-09-13. Retrieved 2023-09-12.
- Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in português do Brasil). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- Russo H, Brès J, Duboin MP, Roquefeuil B (1995). "Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients". European Journal of Clinical Pharmacology. 49 (1–2): 127–37. doi:10.1007/BF00192371. PMID 8751034. S2CID 24285007.
- Morgan DJ, Blackman GL, Paull JD, Wolf LJ (June 1981). "Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section". Anesthesiology. 54 (6): 474–80. doi:10.1097/00000542-198106000-00006. PMID 7235275.
- Ravina, Enrique (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 35. ISBN 9783527326693. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
- World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- Mason, Keira (2021). Pediatric Sedation Outside of the Operating Room: A Multispecialty International Collaboration. Springer Nature. ISBN 9783030584061. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
- "Thiopental sodium Medicinal forms". BNF. Archived from the original on 13 September 2023. Retrieved 12 September 2023.
- Çakırtekin V, Yıldırım A, Bakan N, Çelebi N, Bozkurt Ö (April 2015). "Comparison of the Effects of Thiopental Sodium and Propofol on Haemodynamics, Awareness and Newborns During Caesarean Section Under General Anaesthesia". Turkish Journal of Anaesthesiology and Reanimation. 43 (2): 106–112. doi:10.5152/TJAR.2014.75547. PMC 4917150. PMID 27366476.
- Gleason CA, Juul SE (12 August 2011). Avery's Diseases of the Newborn. Elsevier Health Sciences. p. 169. ISBN 9781455727148. Retrieved 13 August 2016.[permanent dead link]
- Shibata Y, Yokooji T, Itamura R, Sagara Y, Taogoshi T, Ogawa K, et al. (December 2016). "Injury due to extravasation of thiopental and propofol: Risks/effects of local cooling/warming in rats". Biochemistry and Biophysics Reports. 8: 207–211. doi:10.1016/j.bbrep.2016.09.005. PMC 5613958. PMID 28955958.
- Takeko T. "TRAUMA.ORG: Critical Care: Barbiturate Coma". trauma.org. Archived from the original on 19 August 2016. Retrieved 18 August 2016.
- Abraham P, Rennert RC, Gabel BC, Sack JA, Karanjia N, Warnke P, Chen CC (December 2017). "ICP management in patients suffering from traumatic brain injury: a systematic review of randomized controlled trials". Acta Neurochirurgica. 159 (12): 2279–2287. doi:10.1007/s00701-017-3363-1. PMID 29058090. S2CID 3013248.
- Roberts I, Sydenham E (December 2012). "Barbiturates for acute traumatic brain injury". The Cochrane Database of Systematic Reviews. 12 (12): CD000033. doi:10.1002/14651858.CD000033.pub2. PMC 7061245. PMID 23235573.
- Trickey D. "Anesthetic Management of Head-injured Patients". www.amcresidents.com. Archived from the original on 2020-10-18. Retrieved 2020-10-13.
- Royal Dutch Society for the Advancement of Pharmacy (1994). "Administration and Compounding of Euthanasic Agents". The Hague. Archived from the original on 2008-08-21. Retrieved 2008-07-18.
- Pearlman T (December 1980). "Behavioral desensitization of phobic anxiety using thiopental sodium". The American Journal of Psychiatry. American Psychiatric Association. 137 (12): 1580–2. doi:10.1176/ajp.137.12.1580. PMID 6108082.
- "Drugged Future?". TIME. February 24, 1958.
- Snelders S (1998). "The LSD Therapy Career of Jan Bastiaans, M.D". Newsletter of the Multidisciplinary Association for Psychedelic Studies. Multidisciplinary Association for Psychedelic Studies. 8 (1): 18–20. Archived from the original on 2014-04-18. Retrieved 2023-08-18.
- Avram M, Krejcie T, Henthorn T (1990). "[The relationship of age to the pharmacokinetics of early drug distribution: the concurrent disposition of thiopental and indocyanine green.]". Anesthesiology. 72 (3): 403–411. doi:10.1097/00000542-199003000-00002. PMID 2310019.
- "PENTOTHAL". RXList. WebMD. 15 November 2021. Archived from the original on 18 June 2023. Retrieved 18 June 2023.
- "Pentothal (thiopental)". eMedicineHealth. 12 April 2009. Archived from the original on 18 January 2015. Retrieved 15 October 2010.
- James MF, Hift RJ (July 2000). "Porphyrias". British Journal of Anaesthesia. 85 (1): 143–53. doi:10.1093/bja/85.1.143. PMID 10928003. Archived from the original on 2018-12-06. Retrieved 2023-08-18.
- Pereda J, Gómez-Cambronero L, Alberola A, Fabregat G, Cerdá M, Escobar J, et al. (October 2006). "Co-administration of pentoxifylline and thiopental causes death by acute pulmonary oedema in rats". British Journal of Pharmacology. 149 (4): 450–5. doi:10.1038/sj.bjp.0706871. PMC 1978439. PMID 16953192.
- Weber M, Motin L, Gaul S, Beker F, Fink RH, Adams DJ (January 2005). "Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons". British Journal of Pharmacology. 144 (1): 98–107. doi:10.1038/sj.bjp.0705942. PMC 1575970. PMID 15644873.
- Franks NP, Lieb WR (November 1998). "Which molecular targets are most relevant to general anaesthesia?". Toxicology Letters. 100–101 (1–2): 1–8. doi:10.1016/S0378-4274(98)00158-1. PMID 10049127.
- "Anesthesia and Analgesia". University of Virginia School of Medicine. Archived from the original on 2007-05-18. Retrieved 2007-08-05.
- Winters WD, Spector E, Wallach DP, Shideman FE (July 1955). "Metabolism of thiopental-S35 and thiopental-2-C14 by a rat liver mince and identification of pentobarbital as a major metabolite". The Journal of Pharmacology and Experimental Therapeutics. 114 (3): 343–57. PMID 13243246.[dead link]
- Bory C, Chantin C, Boulieu R, Cotte J, Berthier JC, Fraisse D, Bobenrieth MJ (1986). "[Use of thiopental in man. Determination of this drug and its metabolites in plasma and urine by liquid phase chromatography and mass spectrometry]". Comptes Rendus de l'Académie des Sciences, Série III (in français). 303 (1): 7–12. PMID 3093002.
- "This Month in Anesthesia History: March". Anesthesia History Association. Archived from the original on 2011-05-01.
- Steinhaus JE (September 2001). "The Investigator and His 'Uncompromising Scientific Honesty'". ASA Newsletter. American Society of Anesthesiologists. 65 (9): 7–9. Archived from the original on 2011-05-13.
- Lundy JS (April 1966). "From this point in time: some memories of my part in the history of anesthesia". The Journal of the American Association of Nurse Anesthetists. American Association of Nurse Anesthetists. 34 (2): 95–102. PMID 5175948. Archived from the original on 2011-05-01.
- Thatcher VS (1953). "Chapter 7: Illegal or Legal?". History of Anesthesia with Emphasis on the Nurse Specialist. J.B. Lippincott. ISBN 0-8240-6525-5. Archived from the original (PDF) on 2011-05-01.
- Bennetts FE (September 1995). "Thiopentone anaesthesia at Pearl Harbor". British Journal of Anaesthesia. 75 (3): 366–8. doi:10.1093/bja/75.3.366. PMID 7547061.
- "Ohio executes inmate with 1-drug lethal injection". Associated Press. December 2001. Archived from the original on 2015-06-10. Retrieved 2009-12-08.
- Martinez E (8 December 2009). "Kenneth Biros Execution: Ohio Man First to Die Under 1-Drug Thiopental Sodium Method". CBS News. Archived from the original on 12 April 2022. Retrieved 18 August 2023.
- Sullivan J (10 September 2010). "Killer on death row 16-1/2 years is executed". The Seattle Times. Archived from the original on 2 July 2012. Retrieved 18 August 2023.
- "Death Penalty Opposition: EU Set to Ban Export of Drug Used in US Executions". Spiegel Online International. Archived from the original on 21 November 2018. Retrieved 23 January 2014.
- "Drug sold in UK to be used for execution in Georgia". bbc.co.uk. BBC News. 24 January 2011. Archived from the original on 13 April 2016. Retrieved 18 August 2016.
- Casciani D (29 November 2010). "US lethal injection drug faces UK export restrictions". bbc.co.uk. BBC News. Archived from the original on 2 January 2016. Retrieved 18 August 2016.
- "Controls on torture goods - Detailed guidance - GOV.UK". gov.uk. Archived from the original on 2 April 2015. Retrieved 18 August 2016.
- "EU Council Regulation (EU) No 1352/2011". Archived from the original on 2017-07-01. Retrieved 2023-08-18.
- "Truth serum used on 'serial child killers'". Sydney Morning Herald. Reuters. January 12, 2007. Archived from the original on February 15, 2023. Retrieved August 18, 2023.
- Anne Bannon; Stevens, Serita Deborah (2007). The Howdunit Book of Poisons (Howdunit). Cincinnati: Writers Digest Books. ISBN 978-1-58297-456-9.
- Pilkington E (2010-09-28). "US executions delayed by shortage of death penalty drug". Guardian. Archived from the original on 2022-06-18. Retrieved 2022-06-18.
- Welsh-Huggins A (January 21, 2011). "Key death penalty drug discontinued by U.S. maker". NBC News. Archived from the original on 2022-06-18. Retrieved 2022-06-18.
- Solomon D (October 27, 2015). "The FDA Confiscated A Supply Of Execution Drugs Texas Is Thought To Have Imported Illegally". Texas Monthly. Archived from the original on April 13, 2021. Retrieved March 10, 2021.